U.S. patent application number 15/297083 was filed with the patent office on 2017-02-16 for targeting of glycoprotein therapeutics.
This patent application is currently assigned to Genzyme Corporation. The applicant listed for this patent is Genzyme Corporation. Invention is credited to James STEFANO.
Application Number | 20170042979 15/297083 |
Document ID | / |
Family ID | 36951245 |
Filed Date | 2017-02-16 |
United States Patent
Application |
20170042979 |
Kind Code |
A1 |
STEFANO; James |
February 16, 2017 |
TARGETING OF GLYCOPROTEIN THERAPEUTICS
Abstract
Methods of making ligand-decorated polymer conjugates of
therapeutic glycoproteins are described. Improved targeting of
glycoproteins to specific tissues is achieved by masking the
natural carbohydrate and other surface determinants with high
molecular weight polymers, such as, e.g., PEG, polysialic acid,
etc., which in turn are decorated with target-specific ligands. In
some embodiments, acid-labile linkages in such conjugates or
rapidly degradable masking groups allow for the intracellular
release of the polymer from the glycoprotein, for example, under
conditions found in lysosomes.
Inventors: |
STEFANO; James; (Hopkinton,
MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Genzyme Corporation |
Cambridge |
MA |
US |
|
|
Assignee: |
Genzyme Corporation
Cambridge
MA
|
Family ID: |
36951245 |
Appl. No.: |
15/297083 |
Filed: |
October 18, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14534328 |
Nov 6, 2014 |
9498518 |
|
|
15297083 |
|
|
|
|
13354855 |
Jan 20, 2012 |
8906379 |
|
|
14534328 |
|
|
|
|
11970907 |
Jan 8, 2008 |
8124073 |
|
|
13354855 |
|
|
|
|
11398949 |
Apr 5, 2006 |
7341720 |
|
|
11970907 |
|
|
|
|
60668920 |
Apr 6, 2005 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 3/00 20180101; C12Y
302/01022 20130101; A61K 38/47 20130101; A61P 43/00 20180101; A61K
47/64 20170801; C12N 9/2465 20130101; A61K 47/60 20170801; C12N
9/96 20130101; A61K 47/61 20170801 |
International
Class: |
A61K 38/47 20060101
A61K038/47; A61K 47/48 20060101 A61K047/48; C12N 9/40 20060101
C12N009/40; C12N 9/96 20060101 C12N009/96 |
Claims
1. A conjugate comprising: (1) a therapeutic glycoprotein (G), (2)
a masking moiety (M) covalently linked to an oligosaccharide side
chain of the glycoprotein through a first linker (L.sup.1), and (3)
a targeting moiety (T) covalently linked to the masking moiety
through a second linker (L.sup.2), wherein the glycoprotein is
released from the conjugate under lysosomal conditions.
2. The conjugate of claim 1 comprising
G(L.sup.1-M(L.sup.2-T).sub.n).sub.m, wherein 1.ltoreq.n.ltoreq.20
and 1.ltoreq.m.ltoreq.20, independently of each other.
3. The conjugate of claim 1, wherein the glycoprotein is a
non-viral protein chosen from an enzyme and an antibody.
4. The conjugate of claim 3, wherein the enzyme is a lysosomal
enzyme.
5. The conjugate of claim 4, wherein the lysosomal enzyme is
selected from the group consisting of .alpha.-galactosidase A, acid
ceramidase, acid .alpha.-L-fucosidase, glucocerebrosidase, acid
.beta.-galactosidase, iduronate-2-sulfatase, .alpha.-L-iduronidase,
galactocerebrosidase, acid .alpha.-mannosidase, acid
.beta.-mannosidase, arylsulfatase B, arylsulfatase A, arylsulfatase
A, N-acetylgalactosamine-6-sulfate sulfatase, acid
sphingomyelinase, acid .alpha.-glucosidase, .beta.-hexosaminidase
B, heparan N-sulfatase, .alpha.-N-acetylglucosaminidase,
acetyl-CoA:.alpha.-glucosaminiden-acetyltransferase,
N-acetylglucosamine-6-sulfate sulfatase,
.alpha.-N-acetylgalactosaminidase, sialidase, .beta.-glucuronidase,
and .beta.-hexosaminidase A.
6. The conjugate of claim 5, wherein the lysosomal enzyme is chosen
from acid .alpha.-glucosidase and acid sphingomyelinase.
7. The conjugate of claim 5, wherein the lysosomal enzyme is chosen
from .alpha.-galactosidase A and glucocerebrosidase.
8. The conjugate of claim 1, wherein the masking moiety is a
polymer selected the group consisting of polyethylene glycol (PEG),
polyvinylpyrrolidone (PVP), polymethacrylate (PMA), polysialic acid
(PSA), hyaluronic acid (HA), albumin, immunoglobulin (IgG), dextran
sulfate, polyethyleneimine (PEI), polyacrylamide,
.alpha.,.beta.-poly(N-hydroxyethyl)-DL-aspartamide (PHEA),
poly(vinylpyrrolidone-co-dimethyl maleic anhydride
(poly(VP-co-DMMAn), N-(2-hydroxypropyl)methacrylimide) (HMPA) and a
hydroxy alkyl starch (HAS).
9. The conjugate of claim 8, wherein the PEG is a star-PEG or a
pendant-PEG.
10. The conjugate of claim 1, wherein the masking moiety is
degradable under the lysosomal conditions thereby allowing the
release of the glycoprotein.
11. The conjugate of claim 1, wherein the targeting moiety is a
receptor-binding peptide, an antibody to a receptor, or a natural
receptor ligand.
12. The conjugate of claim 1, wherein at least one of the linkers
L.sup.1 and L.sup.2 comprises a labile group which allows the
glycoprotein to be released under the lysosomal conditions.
13. The conjugate of claim 12, wherein the linker comprising the
labile group is L.sup.1.
14. The conjugate of claim 12, wherein the labile group is
acid-labile.
15. The conjugate of claim 14, wherein the acid-labile group is
chosen from hydrazone, imino, ester, and amido.
16. The conjugate of claim 14, wherein the acid-labile group is a
hydrazone group.
17. The conjugate of claim 16, wherein at least one of L.sup.1 and
L.sup.2 comprises a hydrazone-containing group chosen from:
##STR00008## wherein Ar is aryl or heteroaryl.
18. The conjugate of claim 17, wherein at least one of L.sup.1 and
L.sup.2 comprises a hydrazone-containing group chosen from:
##STR00009##
19. The conjugate of claim 1, wherein at least one of L.sup.1 and
L.sup.2 comprises an acid-labile group and a disulfide.
20. The conjugate of claim 19, wherein acid-labile group is chosen
from hydrazone, imino, ester, and amido.
21. The conjugate of claim 19, wherein acid-labile group is a
hydrazone group.
22. The conjugate of claim 19, wherein at least one of L.sup.1 and
L.sup.2 comprises a group chosen from: ##STR00010##
23. The conjugate of claim 1 comprising the formula chosen from:
##STR00011##
24. The conjugate of claim 23 comprising the formula chosen from:
##STR00012##
25. A conjugate comprising: (1) a therapeutic glycoprotein (G), (2)
a first means for masking an oligosaccharide side chain recognition
by its cognate receptor, said first means being covalently linked
to the glycoprotein through a first linker (L.sup.1), and (3) a
second means for targeting the conjugate to a specific tissue or
organ, said first means being covalently linked to the first means
through a second linker (L.sup.2), wherein the glycoprotein is
released from the conjugate under lysosomal conditions.
26. A pharmaceutical composition, comprising the conjugate of claim
1 and a pharmaceutically acceptable excipient.
27. A method of making the conjugate of claim 1, comprising: (i)
providing a masking moiety comprising a first functional group and
a second functional group, (ii) reacting the first functional group
with a carbohydrate side chain of a glycoprotein, and (iii)
reacting the second functional group with a targeting moiety.
28. A method of treating a lysosomal storage disorder in a mammal,
comprising administering to the mammal the conjugate of claim
1.
29. A conjugate comprising: (1) a therapeutic glycoprotein (G), (2)
a masking moiety (M) covalently linked to the glycoprotein through
a first linker (L.sup.1), and (3) a targeting moiety (T) covalently
linked to the masking moiety through a second linker (L.sup.2),
wherein the glycoprotein is released from the conjugate under
lysosomal conditions.
30. The conjugate of claim 29, comprising
G(L.sup.1-M(L.sup.2-T).sub.n).sub.m, wherein 1.ltoreq.n.ltoreq.20
and 1.ltoreq.m.ltoreq.20, independently of each other.
31. The conjugate of claim 29, wherein the glycoprotein is a
non-viral protein chosen from an enzyme and an antibody.
32. The conjugate of claim 31, wherein the enzyme is a lysosomal
enzyme.
33. The conjugate of claim 32, wherein the lysosomal enzyme is
selected from the group consisting of .alpha.-galactosidase A, acid
ceramidase, acid .alpha.-L-fucosidase, glucocerebrosidase, acid
.beta.-galactosidase, iduronate-2-sulfatase, .alpha.-L-iduronidase,
galactocerebrosidase, acid .alpha.-mannosidase, acid
.beta.-mannosidase, arylsulfatase B, arylsulfatase A, arylsulfatase
A, N-acetylgalactosamine-6-sulfate sulfatase, acid
sphingomyelinase, acid .alpha.-glucosidase, .beta.-hexosaminidase
B, heparan N-sulfatase, .alpha.-N-acetylglucosaminidase,
acetyl-CoA:.alpha.-glucosaminiden-acetyltransferase,
N-acetylglucosamine-6-sulfate sulfatase,
.alpha.-N-acetylgalactosaminidase, sialidase, .beta.-glucuronidase,
and .beta.-hexosaminidase A.
34. The conjugate of claim 33, wherein the lysosomal enzyme is
chosen from .alpha.-galactosidase A and glucocerebrosidase.
35. The conjugate of claim 29, wherein the masking moiety is a
polymer selected the group consisting of polyethylene glycol (PEG),
polyvinylpyrrolidone (PVP), polymethacrylate (PMA), polysialic acid
(PSA), hyaluronic acid (HA), albumin, immunoglobulin (IgG), dextran
sulfate, polyethyleneimine (PEI), polyacrylamide,
.alpha.,.beta.-poly(N-hydroxyethyl)-DL-aspartamide (PHEA),
poly(vinylpyrrolidone-co-dimethyl maleic anhydride
(poly(VP-co-DMMAn), N-(2-hydroxypropyl)methacrylimide) (HMPA) and a
hydroxy alkyl starch (HAS).
36. The conjugate of claim 35, wherein the PEG is a star-PEG or a
pendant-PEG.
37. The conjugate of claim 29, wherein the masking moiety is
degradable under the lysosomal conditions thereby allowing the
release of the glycoprotein.
38. The conjugate of claim 29, wherein the targeting moiety is a
non-endogenous protein, a receptor-binding peptide, an antibody to
a receptor, or a natural receptor ligand.
39. The conjugate of claim 29, wherein at least one of the linkers
L.sup.1 and L.sup.2 comprises a labile group which allows the
glycoprotein to be released under the lysosomal conditions.
40. The conjugate of claim 39, wherein the labile group is
acid-labile.
41. The conjugate of claim 40, wherein the acid-labile group is
chosen from hydrazone, imino, ester, and amido.
42. The conjugate of claim 41, wherein the acid-labile group is a
hydrazone group.
43. The conjugate of claim 39, wherein the labile group is a
disulfide.
44. A conjugate comprising: (1) a therapeutic glycoprotein (G), (2)
a masking moiety (M) covalently linked to an amino acid residue of
the glycoprotein through a first linker (L.sup.1), and (3) a
targeting moiety (T) covalently linked to the masking moiety
through a second linker (L.sup.2), wherein the glycoprotein is
released from the conjugate under lysosomal conditions.
45. The conjugate of claim 44, comprising
G(L.sup.1-M(L.sup.2-T).sub.n).sub.m, wherein 1.ltoreq.n.ltoreq.20
and 1.ltoreq.m.ltoreq.20, independently of each other.
46. The conjugate of claim 44, wherein the glycoprotein is a
non-viral protein chosen from an enzyme and an antibody.
47. The conjugate of claim 46, wherein the enzyme is a lysosomal
enzyme.
48. The conjugate of claim 47, wherein the lysosomal enzyme is
selected from the group consisting of .alpha.-galactosidase A, acid
ceramidase, acid .alpha.-L-fucosidase, glucocerebrosidase, acid
.beta.-galactosidase, iduronate-2-sulfatase, .alpha.-L-iduronidase,
galactocerebrosidase, acid .alpha.-mannosidase, acid
.beta.-mannosidase, arylsulfatase B, arylsulfatase A, arylsulfatase
A, N-acetylgalactosamine-6-sulfate sulfatase, acid
sphingomyelinase, acid .alpha.-glucosidase, .beta.-hexosaminidase
B, heparan N-sulfatase, .alpha.-N-acetylglucosaminidase,
acetyl-CoA:.alpha.-glucosaminiden-acetyltransferase,
N-acetylglucosamine-6-sulfate sulfatase,
.alpha.-N-acetylgalactosaminidase, sialidase, .beta.-glucuronidase,
and .beta.-hexosaminidase A.
49. The conjugate of claim 48, wherein the lysosomal enzyme is
chosen from .alpha.-galactosidase A and glucocerebrosidase.
50. The conjugate of claim 44, wherein the amino acid residue is a
lysine residue.
51. The conjugate of claim 44, wherein the masking moiety is a
polymer selected the group consisting of polyethylene glycol (PEG),
polyvinylpyrrolidone (PVP), polymethacrylate (PMA), polysialic acid
(PSA), hyaluronic acid (HA), albumin, immunoglobulin (IgG), dextran
sulfate, polyethyleneimine (PEI), polyacrylamide,
.alpha.,.beta.-poly(N-hydroxyethyl)-DL-aspartamide (PHEA),
poly(vinylpyrrolidone-co-dimethyl maleic anhydride
(poly(VP-co-DMMAn), N-(2-hydroxypropyl)methacrylimide) (HMPA) and a
hydroxy alkyl starch (HAS).
52. The conjugate of claim 51, wherein the PEG is a star-PEG or a
pendant-PEG.
53. The conjugate of claim 44, wherein the masking moiety is
degradable under the lysosomal conditions thereby allowing the
release of the glycoprotein.
54. The conjugate of claim 44, wherein the targeting moiety is a
non-endogenous protein, a receptor-binding peptide, an antibody to
a receptor, or a natural receptor ligand.
55. The conjugate of claim 44, wherein at least one of the linkers
L.sup.1 and L.sup.2 comprises a labile group which allows the
glycoprotein to be released under the lysosomal conditions.
56. The conjugate of claim 54, wherein the labile group is a
disulfide.
57. The conjugate of claim 56, wherein at least one of the linkers
L.sup.1 and L.sup.2 comprises a disulfide selected from:
##STR00013## wherein 2.ltoreq.p.ltoreq.12.
58. The conjugate of claim 55, wherein the labile group is
acid-labile.
59. The conjugate of claim 58, wherein the acid-labile group is
chosen from hydrazone, imino, ester, and amido.
60. The conjugate of claim 59, wherein the acid-labile group is a
hydrazone group.
61. The conjugate of claim 60, wherein at least one of L.sup.1 and
L.sup.2 comprises a group selected from: ##STR00014## wherein Ar is
aryl or heteroaryl.
62. The conjugate of claim 56, comprising the formula: ##STR00015##
wherein 2.ltoreq.p.ltoreq.12 and 2.ltoreq.q.ltoreq.12,
independently of each other.
63. The conjugate of claim 12, wherein the labile group comprises a
disulfide.
64. The conjugate of claim 63, wherein at least one of the linkers
L.sup.1 and L.sup.2 comprises a disulfide selected from:
##STR00016## wherein 2.ltoreq.p.ltoreq.12.
65. A pharmaceutical composition, comprising the conjugate of claim
44 and a pharmaceutically acceptable excipient.
66. A method of making the conjugate of claim 44, comprising: (i)
providing a masking moiety comprising a first functional group and
a second functional group, (ii) reacting the first functional group
with an amino acid residue of a glycoprotein, and (iii) reacting
the second functional group with a targeting moiety.
67. A method of treating a lysosomal storage disorder in a mammal,
comprising administering to the mammal the conjugate of claim 44.
Description
[0001] This is a continuation of U.S. patent application Ser. No.
13/354,855, filed Jan. 20, 2012, which is a divisional application
of U.S. patent application Ser. No. 11/970,907, filed Jan. 8, 2008,
now U.S. Pat. No. 8,124,073, which is a continuation application of
U.S. patent application Ser. No. 11/398,949, filed Apr. 5, 2006,
now U.S. Pat. No. 7,341,720, which claims the benefit of U.S.
Provisional Patent Application No. 60/668,920, filed Apr. 6, 2005,
all of which are incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The invention relates to protein therapeutics and, more
specifically, to conjugation of such therapeutics with other
molecular moieties to achieve tissue-specific targeting in the
body, followed by the intracellular release of the biologically
active therapeutic at the site of action, as exemplified by
replacement lysosomal enzymes conjugated with ligand-decorated
polymers and the use of such conjugates for treatment of lysosomal
storage disorders.
BACKGROUND OF THE INVENTION
[0003] Tissue-specific targeting of therapeutic proteins to tissues
of choice in the body finds application in many medical conditions
including cancer and a number of acquired and inherited disorders.
For example, in the class of diseases called lysosomal storage
disorders, an inherited deficiency in one or more enzymes which
reside in the lysosomes leads to the accumulation of substrates for
those enzymes in the cells. Because of tissue-specific patterns of
expression and accumulation of the substrates within different
cells in the body, these disorders result in tissue/organ-specific
manifestations which vary depending upon the disorder. These
disorders have been found to be treatable by intravenous
administration of the active version of the enzyme deficient in the
patient, a process termed enzyme replacement therapy (ERT).
However, the efficacy of ERT varies widely among the different
disorders. Although the reasons for this variability are not fully
understood, it is commonly believed to be due to the lack of
specific targeting to the most seriously affected tissues.
[0004] Most lysosomal proteins are glycoproteins containing one or
more N- or O-linked oligosaccharide side chains of high mannose,
complex or hybrid type. A number of receptors specific for these
sugar residues exist, including among others, those for mannose,
galactose (asialoglycoprotein receptor, ASGPR) and
mannose-6-phosphate (cation-independent mannose-6-phosphate
receptor, CIMPR). These receptors at least in part mediate the
uptake of administered protein into cells. However, the
distribution of these receptors within tissues in the body (e.g.,
ASGPR expressed on liver hepatocytes, mannose receptor on cells of
the reticulo-endothelial system such as macrophages and Kupffer
cells of the liver and CIMPR expressed widely on endothelial cells
as well as other cell types) is not optimal for targeting proteins
to the tissues which are most strongly affected. In some cases,
modification and/or removal of a portion or all of the
oligosaccharide chains through a process termed remodeling can
advantageously improve the ultimate biodistribution of the proteins
to more specifically target the protein to desired cell types (see,
e.g., Furbush et al. Biochimica et Biophysica Acta 673:425-434
(1981), which describes sugar remodeling for a recombinant
glucocerebrosidase, imiglucerase (Cerezyme.RTM., Genzyme
Corporation, Cambridge, Mass.)). However, complete removal of the
carbohydrate side chains is often counterproductive, since they are
also often necessary for the solubility and/or intracellular
stability of the protein.
[0005] Another difficulty encountered with ERT is the strong
immunogenicity of some therapeutic proteins as the patient's immune
system often recognizes such proteins as foreign and mounts a
neutralizing immune response. Thus, a means to reduce the exposure
of the therapeutic proteins to the immune system would also be
desirable.
[0006] Covalent conjugation with polymers such as polyethylene
glycol (PEG) generally increases the serum half-life of a number of
therapeutics such as antibodies, interferon, and effector
molecules, while also reducing their immunogenicity. Although
maintaining elevated concentrations of administered lysosomal
proteins in circulation would similarly be expected to increase
their bioavailability, in the case of lysosomal proteins,
conjugation of these proteins with PEG ("PEGylation") alone does
not appear to be effective. This may partly be due to the adverse
effect of the conditions in plasma, particularly elevated pH, on
enzyme stability, and also on the inability of PEG, a neutral
hydrophilic polymer, to influence the relative affinity of the
glycoproteins for various receptor systems and to introduce any new
tissue tropism to the protein. Thus, an additional means to promote
uptake into the lysosomes of cells, and specifically the cells in
those tissues in which substrate has accumulated in the body, would
be highly desirable. In some cases, this can be achieved by the
affinity of the polymer itself for specific tissue types (e.g.,
PVP-DMMan polymer conjugates for targeting a therapeutic to the
kidneys are described in Kamada et al., Nat. Biotech. (2003)
21:399-404). Alternatively, it may be achieved by the introduction
of ligands into the conjugate to promote interaction with
tissue-specific receptors to mediate uptake. In the simplest case,
such ligands are represented by antibodies against the receptor of
choice. However, the larger proteinaceous ligands, such as
antibodies, can themselves be immunogenic, thus posing significant
challenges in the clinic.
[0007] Additionally, conjugation of a therapeutic protein with high
molecular weight polymers may interfere with the activity of the
protein at the site of action in the cell. For example, it has been
found that many of the lysosomal enzymes, particularly those that
act on glycolipid substrates, require a cofactor from the class
termed saposins for their enzymatic activity. Saposins are believed
to assist in presentation of the carbohydrate head group of the
substrate to the catalytic site. Thus, conjugation of a high
molecular weight polymer to the enzyme might affect the enzyme's
activity by interfering with interactions with saposins, thereby
lowering the efficacy of the therapeutic. Accordingly, a means to
provide for elimination of the polymer from the enzyme in the site
of action would be desirable.
[0008] On the other hand, another factor contributing to lowered
efficacy of enzyme replacement therapies is the instability of
lysosomal proteins within the lysosome, leading to a need for
repeated administration. For example, Cerezyme.RTM.
(glucocerebrosidase) is generally administered to a patient having
Gaucher's disease on a biweekly basis due to loss of its activity
after being taken up by target cells. The loss of activity is at
least in part due to the action of lysosomal proteases on the
protein, and appending polymers such as PEG can increase the
resistance of proteins to proteolysis. Thus, under certain
circumstances, a polymer may serve the additional function of
protecting the protein in the lysosomal environment, thereby
providing better intralysosomal stability of the active protein.
Such a strategy may be effective in reducing the frequency of
administration.
[0009] Low molecular weight ligands, such as peptides or mono- or
oligosaccharides, may be used for targeting a therapeutic protein.
However, such ligands often must be present in multiple copies on a
macromolecule in order to mediate effective uptake by the cognate
receptor, a condition termed "multivalent display." Although
current commercially available heterobifunctional PEGs (e.g.,
linear molecules containing different chemical entities on each
terminus) may be used to generate ternary conjugates, they do not
provide for multivalent display except by the attachment of
multiple PEG molecules. But such heavy modification often has an
adverse effect on enzyme activity.
[0010] Therefore, there exists a continuing need to provide protein
therapeutics that allow for target-specific delivery within the
body and are sufficiently biologically active upon intracellular
uptake.
SUMMARY OF THE INVENTION
[0011] The present invention provides ternary conjugates of a
therapeutic glycoprotein, a masking moiety, and a targeting moiety.
A conjugate of the invention includes:
[0012] (1) a therapeutic glycoprotein (G),
[0013] (2) a masking moiety (M) covalently linked to an
oligosaccharide side chain of the glycoprotein through a first
linker (L.sup.1), and
[0014] (3) a targeting moiety (T) covalently linked to the masking
moiety through a second linker (L.sup.2),
[0015] wherein the glycoprotein is released from the conjugate
under lysosomal conditions.
[0016] In other embodiments, a conjugate includes:
[0017] (1) a therapeutic glycoprotein (G),
[0018] (2) a masking moiety (M) covalently linked to an amino acid
residue of the glycoprotein through a first linker (L.sup.1),
and
[0019] (3) a targeting moiety (T) covalently linked to the masking
moiety through a second linker (L.sup.2),
[0020] wherein the glycoprotein is released from the conjugate
under lysosomal conditions.
[0021] In some embodiments, the therapeutic glycoprotein is a
lysosomal enzyme, such as, e.g., lysosomal enzymes listed in Table
2, including in particular, glucocerebrosidase,
.alpha.-galactosidase A, acid .alpha.-glucosidase, or acid
sphingomyelinase. In some embodiments, the therapeutic glycoprotein
is glucocerebrosidase or .alpha.-galactosidase A.
[0022] In some embodiments, L.sup.1 and/or L.sup.2 comprise(s) one
or more labile groups such as, e.g., a hydrazone and/or a disulfide
group, that allow for a biologically active glycoprotein to be
released at the site of action in the cells, e.g., in the
lysosome.
[0023] In some embodiments, the masking moiety is a polymer
selected the group consisting of polyethylene glycol (PEG),
polyvinylpyrrolidone (PVP), polymethacrylate (PMA), polysialic acid
(PSA), hyaluronic acid (HA), hydroxy alkyl starches (HAS), albumin,
and dextran.
[0024] The invention further encompasses methods of making and
using the conjugates of the inventions. The conjugates can be used,
for example, as pharmaceutical compositions, e.g., for treatment of
lysosomal storage disorders listed in Table 2. In some embodiments,
the lysosomal storage disorder is Fabry, Gaucher, Pompe or Niemann
Pick B disease.
BRIEF DESCRIPTION OF THE DRAWINGS
[0025] FIG. 1 depicts a structural representation of a nonlimiting
embodiment of the invention. G, M, and T denote a glycoprotein, a
masking moiety, and a targeting moiety, respectively. Linkers
L.sup.1 and L.sup.2 are not shown.
[0026] FIG. 2 depicts a scheme for conjugating a therapeutic
glycoprotein to a hydrazide-PEG. Terminal sialic acids on the
glycoprotein are removed by treatment with neuraminidase. The
exposed terminal galactose residues are then oxidized to aldehydes
by treatment with Dactylium dendroides galactose oxidase.
Alternatively, aldehydes may be introduced through oxidation with
sodium periodate. The product is then exchanged into buffer around
pH 5.5 and reacted with a hydrazide PEG to form a hydrazone
conjugate. The products are purified away from unreacted PEG (e.g.,
by anion exchange or size-exclusion chromatography).
[0027] FIG. 3 shows a scheme for generating a
peptide-PEG-glycoprotein conjugate using a heterobifunctional PEG.
A heterobifunctional PEG is generated by reacting a
hydrazide-functionalized PEG with an adapter molecule
(glyoxyl-nipsylethylamide, "GNEA") containing a hydrazide-reactive
glyoxyl aldehyde linked to a thiol reactive functional group
(nipsylethylamine, "NEA"). This PEG is reacted in the presence of
galactose oxidase with neuraminidase-treated protein to produce a
conjugate in which the PEG is coupled through a hydrazone linkage
to an exposed protein oligosaccharide. This product is purified,
and then coupled to a peptide containing a free thiol.
[0028] FIG. 4A illustrates the generation of a
peptide-PEG-glycoprotein conjugate using thiol/hydrazide chemistry.
Aldehyde groups are generated on the glycoprotein by treatment with
periodate or galactose oxidase (GAO) as in FIG. 1. The GAO-treated
protein is reacted with a linker containing a hydrazide and a
protected thiol, such as 3-(2-pyridyldithio)propionyl hydrazide
(PDPH). The linker is then reduced (e.g., with
tris-carboxyethylphosphine, TCEP) to expose the thiol, which is
then reacted with a PEG molecule bearing thiol-reactive moieties.
The resulting conjugate is purified (e.g., by ion-exchange
chromatography) and reacted with peptides containing a cysteine
moiety to yield a final ternary peptide/PEG/glycoprotein
conjugate.
[0029] FIG. 4B illustrates conjugation of the glycoprotein through
an amino acid residue. An amino acid residue, in this illustration
a lysine, is reacted with S-acetyl-dPEG.TM..sub.p NHS ester to
introduce a thiol group on the glycoprotein. The acetyl-protected
thiol is deprotected with hydroxylamine and reacted with an NEA-PEG
to produce a disulfide linked NEA-PEG/glycoprotein conjugate. A
targeting moiety bearing a protected thiol, such as a protein
modified with S-acetyl-dPEG.TM..sub.q NHS ester, is deprotected and
reacted with the NEA-PEG/glycoprotein conjugate to produce the
final ternary protein/PEG/glycoprotein conjugate.
[0030] FIG. 5 shows the pH-dependent dissociation of a pendant
hydrazide PEG conjugate with .alpha.-galactosidase A. A pendant
hydrazide PEG bearing on average eight propionic acid hydrazide
groups was conjugated with galactose-oxidized .alpha.-galactosidase
as described for FIG. 1. The conjugate was purified by anion
exchange chromatography and exchanged into buffers of varying pH
and incubated overnight at 37.degree. C. as described in Example 2.
The amount of protein in PEGylated form relative to an unincubated
control was determined by densitometry of the Coomassie-stained gel
following SDS-PAGE.
[0031] FIG. 6 shows results of a BIAcore.TM. analysis for the
interaction of PEG-glycoprotein conjugates with the cation
independent mannose-6-phosphate receptor (CIMPR). The extent of
unmodified .alpha.-galactosidase or galactosidase conjugate binding
to CIMPR (in RU) was determined using immobilized soluble CIMPR on
a dextran-coated chip. Two hydrazide PEGs (10 kDa MW, SunBio) were
used for preparing the conjugates by the scheme shown in FIG. 1:
(1) a 4-arm star-type PEG (dendrimer; Hz4PEG) and (2) an 8-arm
pendant PEG (Hz8PEG). Both were functionalized with hydrazide
groups either at the PEG termini (Hz4PEG) or internally by random
co-polymerization (Hz8PEG). This shows 10-fold higher
concentrations of the Hz4-PEG conjugate were required to obtain the
same degree of receptor binding as obtained with unmodified
.alpha.-galactosidase.
[0032] FIG. 7 shows results of a pharmacokinetics study with
intravenously administered .alpha.-galactosidase and a
PEG-.alpha.-galactosidase conjugate in Fabry mice. An initial blood
sample was drawn prior to protein injection (plotted as zero time).
Proteins were injected at 1 mg/kg body weight by tail vein and
blood withdrawn at 0.5, 1, 2, 4, and 8 hours. Serum was prepared
and assayed for galactosidase activity using a 4MU substrate as
described in Example 4.
[0033] FIG. 8 shows biodistribution of .alpha.-galactosidase
(Fabrazyme.RTM.) or PEG-Fabrazyme.RTM. conjugate in Fabry mice.
Proteins were injected at 1 mg/kg body weight and the organs
harvested 8 hours after injection. Galactosidase activity was
determined using a 4MU substrate as described in Example 4.
[0034] FIG. 9 is intracellular uptake levels of various
peptide-PEG-.alpha.-galactosidase conjugates. NEA-PEG conjugates
prepared as described in Example 7 were coupled with various
peptides (SEQ ID NOs:2-6) as described, and incubated with murine
fibroblasts expressing the cation-independent mannose-6-phosphate
(M6P) receptor overnight. In two cases, 2 mM free M6P was added to
the culture medium with peptide conjugates ("+M6P").
BRIEF DESCRIPTION OF THE SEQUENCES
TABLE-US-00001 [0035] TABLE 1 Sequences appearing in the Sequence
Listing De- SEQ ID NO Sequence scription SEQ ID NO: 1
GKKKKKKKKKGC-amide K9 SEQ ID NO: 2 CF-GGGYGRKKGGQRRRGGGC- Tat *
amide SEQ ID NO: 3 CF-GGGGGKGGGKGGGGGC-amide K2 SEQ ID NO: 4
CF-GGGKKKKKKKKKGGGC-amide K9 SEQ ID NO: 5 CF-GGGkkkkkkkkkGGG-amide
k9 ** SEQ ID NO: 6 Biotin-GRRRRRRRRRGC-OH R9 SEQ ID NO: 7
THRPPMWSPVWP SEQ ID NO: 8 ASSLNIA SEQ ID NO: 9 CKGGRAKDC SEQ ID NO:
10 GETRAPL *-carboxyfluorescein; ** k-(D) lysine.
DETAILED DESCRIPTION OF THE INVENTION
Ternary Conjugates
[0036] The present invention provides ternary conjugates
comprising: [0037] (1) a therapeutic glycoprotein (G), [0038] (2)
at least one masking moiety (M) covalently linked to the
glycoprotein through a first linker (L.sup.1), and [0039] (3) at
least one targeting moiety (T) covalently linked to the masking
moiety through a second linker (L.sup.2), wherein the therapeutic
glycoprotein is released from the conjugate under lysosomal
conditions thereby yielding a biologically active glycoprotein at
the site of action in the cell, e.g., in the lysosome.
[0040] In one embodiment, the conjugate comprises: [0041] (1) a
therapeutic glycoprotein (G), [0042] (2) at least one masking
moiety (M) covalently linked to an oligosaccharide side chain of
the glycoprotein through a first linker (L.sup.1), and [0043] (3)
at least one targeting moiety (T) covalently linked to the masking
moiety through a second linker (L.sup.2), wherein the therapeutic
glycoprotein is released from the conjugate under lysosomal
conditions thereby yielding a biologically active glycoprotein at
the site of action in the cell, e.g., in the lysosome.
[0044] In another embodiment, the conjugate comprises: [0045] (1) a
therapeutic glycoprotein (G), [0046] (2) at least one masking
moiety (M) covalently linked to an amino acid residue of the
glycoprotein through a first linker (L.sup.1), and [0047] (3) at
least one targeting moiety (T) covalently linked to the masking
moiety through a second linker (L.sup.2), wherein the therapeutic
glycoprotein is released from the conjugate under lysosomal
conditions thereby yielding a biologically active glycoprotein at
the site of action in the cell, e.g., in the lysosome.
[0048] The term "biologically active" refers to a function or set
of functions (or the effect to which the function is attributed)
performed by a molecule in a biological system in vivo or in vitro.
Biological activity may be assessed by, for example, enzymatic
activity or inhibitory activity as described in the Examples.
[0049] The release of the therapeutic glycoprotein may occur as a
result of degradation of L.sup.1, M, or both at the site of action.
Optionally, L.sup.2 may also be degradable at the site of
action.
[0050] In some embodiments, the ternary conjugates are rapidly
degradable at the site of action in a cell. The term "rapidly
degradable" means that up to 50%, 60%, 70%, 80%, 90%, or
substantially all of the glycoprotein is released from the
conjugate within 48 hours under lysosomal conditions. (The time can
be measured from the time of the administration to a subject or
from the time of intracellular uptake). In such embodiments, the
half-life of the conjugate (the time at which 50% of the
administered glycoprotein is released) is less than 48 hours, e.g.,
about 6, 12, 18, 24, 30, 36, 42, and 46 hours. The conjugate can be
rapidly degradable due to the masking moiety or a linker, or
both.
[0051] The term "lysosomal conditions" refers to conditions within
the lysosome. The lysosome is a cytoplasmic organelle which, when
isolated under appropriate conditions, displays one or more
lysosomal hydrolase activities. Lysosomal isolation procedures are
described in e.g., Bonifacino et al. (eds.) Current Protocols in
Cell Biology, John Wiley & Sons, Inc., 2002, section 3.6. In
general, the lysosomal conditions may be reproduced in vitro and
include a pH of about 4.5-5.5 and a reducing environment as
illustrated in the Examples.
[0052] In other embodiments, the ternary conjugates are slowly
degradable at the site of action in a cell. The term "slowly
degradable" means that less than 50%, 40%, 30%, 20%, 10% or
substantially none of the glycoprotein is released from the
conjugate after approximately 48 hours under lysosomal conditions.
In such embodiments, the half-life of the conjugate is more than 48
hours, e.g., 50, 96, 168, 216, 240, 360, or 480 hours. The
conjugate can be slowly degradable due to the masking moiety or a
linker, or both.
[0053] The ternary conjugates of the invention may comprise as many
as 20 masking moieties (M), each independently linked to at least
one and as many as 20 targeting moieties (T). Generally, a
conjugate of the invention or a part thereof has the following
formula:
G(L.sup.1-M(L.sup.2-T).sub.n).sub.m (I)
where n and m are integers; and 1.ltoreq.n.ltoreq.20 and
1.ltoreq.m.ltoreq.20, independently of each other. n and/or m may,
for example, be chosen from 2 to 16, 4 to 12, 1 to 8, or 2 to 4.
For example, a particular conjugate molecule may comprise two
masking moieties M, with one of the two masking moieties comprising
4 targeting moieties, while the other masking moiety may comprise
12 targeting moieties. For illustration purposes only and without
limitation, FIG. 1 provides a schematic structural representation
of a hypothetical conjugate molecule containing m masking moieties
and a varying number (q.sub.m) of targeting moieties associated
with each masking moiety (linkers are omitted from the figure).
Masking moieties M may be the same or different; linkers L.sup.1
may be same or different; targeting moieties T may be the same or
different. Additionally, there could be one or more masking
moieties that do not have any L.sup.2-T or T attached thereto so
long as there is at least, on average, one masking moiety that
does. Similarly, there could be one or more L.sup.1 that do not
have any M. Thus, the ratio of number of targeting moieties to the
number of masking moieties in a conjugate composition may be less
than 1, e.g., as low as 0.1. Likewise, the ratio of the number of
masking moieties per the number of G's in a conjugate composition
may be less than 1, e.g., as low as 0.1. The embodiments with
n.gtoreq.2 may provide an additional advantage of "multivalent
display" of the targeting moiety, which may allow enhanced
intracellular uptake under some conditions.
Glycoprotein
[0054] The term "therapeutic glycoprotein" refers to a protein that
bears one or more O- and/or N-linked oligosaccharide side chain(s)
such that when the glycoprotein is delivered intracellularly, it
will exert a therapeutic effect such as, e.g., the prevention,
delayed onset, or amelioration of symptoms in a patient or
otherwise produce a desired biological outcome, such as, e.g., an
improved organelle, cell, tissue, or organ function due to, for
example, reduced substrate accumulation, reduced cell growth,
induction of apoptosis, etc. In some embodiments, the therapeutic
glycoprotein is a nonviral glycoprotein, e.g., an antibody. One
class of therapeutic glycoproteins is enzymes that are deficient in
a patient to be treated. Examples of such enzymes include lysosomal
enzymes such as lysosomal hydrolases listed in Table 2. In some
embodiments, the therapeutic glycoprotein is .alpha.-Galactosidase
A, acid .beta.-glucosidase (glucocerebrosidase), acid
.alpha.-glucosidase or acid sphingomyelinase In some embodiments,
the therapeutic glycoprotein is .alpha.-Galactosidase A, or acid
.beta.-glucosidase (glucocerebrosidase).
TABLE-US-00002 TABLE 2 Lysosomal Storage Disorders and
Corresponding Glycoproteins Defective enzyme/Therapeutic Lysosomal
storage disorder glycoprotein Fabry .alpha.-Galactosidase A Farber
Acid ceramidase Fucosidosis Acid .alpha.-L-fucosidase Gaucher types
1, 2, and 3 Acid .beta.-glucosidase (glucocerebrosidase) G.sub.M1
gangliosidosis* Acid .beta.-galactosidase Hunter
Iduronate-2-sulfatase Hunter-Scheie .alpha.-L-Iduronidase Krabbe
Galactocerebrosidase .alpha.-Mannosidosis Acid .alpha.-mannosidase
.beta.-Mannosidosis Acid .beta.-mannosidase Maroteaux-Lamy
Arylsulfatase B Metachromatic leukodystrophy Arylsulfatase A
Morquio A N-Acetylgalactosamine-6-sulfate sulfatase Morquio B Acid
.beta.-galactosidase Niemann-Pick Acid sphingomyelinase Pompe Acid
.alpha.-glucosidase Sandhoff* .beta.-Hexosaminidase B Sanfilippo A
Heparan N-sulfatase Sanfilippo B .alpha.-N-Acetylglucosaminidase
Sanfilippo C Acetyl-CoA: .alpha.-glucosaminide N-acetyltransferase
Sanfilippo D N-Acetylglucosamine-6-sulfate sulfatase
Schindler-Kanzaki .alpha.-N-acetylgalactosaminidase Sialidosis
Sialidase Sly .beta.-Glucuronidase Tay-Sachs* .beta.-Hexosaminidase
A *Diseases resulting from the storage of glycosylceramide-based
glycosphingolipids.
[0055] The therapeutic glycoprotein may contain two or more
subunits (such as, e.g., .alpha.-galactosidase A which is a
homodimer of two 45 kDa subunits) with one or more of these
subunits bearing at least one oligosaccharide chain.
Targeting Moiety
[0056] The targeting moiety is selected based on the target cell
type, tissue, or organ to allow sufficiently specific delivery of
the therapeutic glycoprotein to the desired target. Examples of
targeting moieties include:
[0057] (1) transducing peptides such as, e.g., R9 (SEQ ID NO:6)
(Mitchell et al., J. Peptide Res. (2000) 56:318-325; Wender et al.,
Proc. Natl. Acad. Sci. (2000) 97:13003-13008), K9 (SEQ ID NO:4)
(Shen et al., Proc. Natl. Acad. Sci. (1978) 75:1872-76; U.S. Pat.
No. 4,701,521), Tat (SEQ ID NO:2) (Mann et al., EMBO J. (1991)
10:1733-39; Fawell et al., Proc. Natl. Acad. Sci. (1994)
91:664-668; Schwarze et al., Science (1999) 285:1569-72),
SynB1-SynB6 and sequence variants thereof (Roussele et al., Mol.
Pharmacol. (2000) 57:679-686; Day et al., J. Immunol. (2003)
170:1498-1503, antennapedia (Derossi et al., Trends in Cell Biol.
(1998) 8:84-87), VP22 (Elliott et al., Cell (1997) 88:223-233);
[0058] (2) natural receptor ligands such as, e.g., insulin (U.S.
Pat. No. 4,749,570) for targeting through the insulin receptor,
insulin-like growth factor II (IGF-II) (U.S. Patent Appln. Pub. No.
2003/0082176) for targeting through the cation-independent mannose
6-phosphate receptor (CIMPR), and receptor-associated protein (RAP)
(Prince et al. J. Biol. Chem. (2004) 279:35037-35046) for targeting
through LDLR-related protein (LRP), and melanotransferrin (Demeule
et al. J. Neurochem. (2002) 83:924-933 for targeting through a
member of the LDL receptor family to brain;
[0059] (3) phage-display selected peptide ligands such as, e.g.,
Sp8ca (WO 01/90139) for targeting to brain, ASSLNIA (SEQ ID NO:8)
(U.S. Pat. No. 6,399,575) for targeting to muscle, CKGGRAKDC (SEQ
ID NO:9) (Kolonin et al., Nature Med. (2004) 10:625-32) for
targeting to adipose tissue, GETRAPL (SEQ ID NO:10) (U.S. Pat. No.
6,399,575) for targeting to muscle or brain; and THRPPMWSPVWP (SEQ
ID NO:7) (Lee et al., Eur. J. Biochem. (2001) 268:2004-2012) for
targeting through the transferrin receptor to the brain;
[0060] (4) fragments of endogenous proteins such as tissue factor
pathway inhibitor (TFPI) (Hembrough et al., Blood (2004)
103:3374-3380) for targeting through Very Low Density Lipoprotein
(VLDL) receptor;
[0061] (5) antibodies to receptors such as, e.g., the
anti-transferrin receptor antibody OX26 (Frieden et al., J. Pharm.
Exp. Ther. (1996) 278:1491-98; Schnyder et al., Biochem. J. (2004)
377:61-7) and other anti-transferrin receptor antibodies (Friden et
al. 1996; Zhang et al., Mol. Therapy (2003) 4:1-8 for targeting to
the brain; the anti-insulin receptor antibody 83-14hIRMab (Zhang et
al., Mol. Therapy (2003) 7:1-8); the anti-Fc44 antibody (WO
02/057445; Muruganandam et al., FASEB J. (2002) 16:240-242);
[0062] (6) small molecules such as, e.g., bisphosphonates for
targeting to bone; and
[0063] (7) non-endogenous proteins and fragments thereof, such as,
e.g., diphtheria toxin CRM.sub.197, for targeting heparin-binding
epidermal growth factor precursor (HB-EGF) present on the surface
of cells in the heart and lung and the blood brain barrier
(Gaillard P J, et al. Expert Opin. Drug Deliv. 2005 2(2): 299-309;
Abraham et al. BBRC (1993) 190:125-133).
[0064] Additional targeting moieties can be made, e.g., as
described in Cabilly (ed.), Combinatorial Peptide Library
Protocols, 1st ed., Humana Press, 1998; Jung (ed.), Combinatorial
Peptide and Nonpeptide Libraries: A Handbook, 1997, John Wiley
& Sons; and Antibodies: A Laboratory Manual, Harlow et al.
(eds.) Cold Spring Harbor Laboratory, 1988; and Borrebaeck (ed.)
Antibody Engineering, 2nd ed., 1995, Oxford University Press.
Masking Moiety
[0065] A masking moiety is used to mask the oligosaccharide side
chain of the glycoprotein from being recognized by its cognate
receptor. For example, a masking moiety should be of sufficient
size or bulk to reduce (or completely block) the binding of the
glycoprotein to its cognate receptor by at least 30%, 40%, 50%,
60%, 70% or more. Suitable methods for measuring the reduction or
blockage of the glycoprotein-receptor are illustrated in the
Examples.
Examples of Masking Moieties Include the Following:
[0066] (1) non-naturally occurring biocompatible polymers such as,
e.g., polyalkylene oxides, polyethylene glycol (PEG),
polyvinylpyrrolidone (PVP), and polymethacrylate (PMA),
polyethyleneimine (PEI), polyacrylamide,
.alpha.,.beta.-poly(N-hydroxyethyl)-DL-aspartamide (PHEA, Cavallaro
et al., J. Drug Target. (2004) 12:593-605),
poly(vinylpyrrolidone-co-dimethyl maleic anhydride
(poly(VP-co-DMMAn) Kamada et al., Nature Biotechnology (2003)
21:399-404), N-(2-hydroxypropyl)methacrylimide) (HMPA, Etrych et
al., J. Controlled Release (2001) 73:89-102.)
[0067] (2) polyanionic polysaccharides such as, e.g., polysialic
acids (PSA) (e.g., colomininic acid), hyaluronic acid (HA), and
dextran sulfate; and hydroxy alkyl starches (e.g., hydroxy methyl
starch, hydroxy ethyl starch, hydroxy propyl starch, etc.).
[0068] (3) proteinaceous polymers such as, e.g., albumin (e.g.,
human serum albumin (HSA), immunoglobulin (IgG).
[0069] In some embodiments, the masking moiety is rapidly
degradable under lysosomal conditions. The term "rapidly
degradable" when used in reference to a masking moiety means that
the masking moiety is degraded so that up to 50%, 60%, 70%, 80%,
90%, or substantially all of the glycoprotein is released from the
conjugate within 48 hours thereby yielding a biologically active
glycoprotein at the site of action in the cell. In such
embodiments, the half-life of the release is less than 48 hours,
e.g., about 6, 12, 18, 24, 30, 36, 42, and 46 hours. Rapidly
degradable masking moieties may be synthesized from, e.g., PSA or
HA.
[0070] In other embodiments, the masking moiety is "slowly
degradable" under the lysosomal conditions, i.e., it is more
resistant to degradation and provides for a more prolonged supply
of biologically active glycoprotein at the site of action in the
cell. The term "slowly degradable" when used in reference to a
masking moiety means that the masking moiety is degraded so that
less than 50%, 40%, 30%, 20%, 10% or substantially none of the
glycoprotein is released from the conjugate after approximately 48
hours under the lysosomal conditions. In such embodiments, the
half-life of the release is more than 48 hours, e.g., 50, 96, 168,
216, 240, 360, or 480 hours. Slowly degradable masking moieties may
be synthesized from, e.g., PEG, PVP, or hydroxyethyl starch.
[0071] The masking moiety may have a molecular weight of, for
example, 0.5-100, 1-50, or 10-20 kDa. The masking moiety may
comprise one or more (e.g., 2 to 40, 2 to 20, 2 to 10, 3, 4, or 5)
functional groups for conjugation to the glycoprotein and the
targeting moiety. For example, when the masking moiety is PEG, the
PEG may comprise multiple arms in either a pendant or star
configuration, such as a pendant 8- or 16-arm PEG, or a star
configuration 4- or 6-arm PEG, or block copolymers containing PEG
groups such as described in, e.g., Funhoff et al., J. Control.
Release (2005) 102:711-724; Lecolley et al. Chem. Comm. (2004)
18:2026-2027.
Linkers
[0072] The linkers L.sup.1 and L.sup.2 serve to covalently bind the
masking moiety to the glycoprotein and the targeting moiety,
respectively. In some embodiments, L.sup.1 and/or L.sup.2 each
comprises a labile group that allows for the therapeutic
glycoprotein to be released from the conjugate under lysosomal
conditions thereby yielding a biologically active glycoprotein at
the site of action in the cell.
[0073] In some embodiments, L.sup.1 and/or L.sup.2 are/is rapidly
degradable under lysosomal conditions. The term "rapidly
degradable", when used in reference a linker, means that the linker
is degraded so that up to 50%, 60%, 70%, 80%, 90%, or substantially
all of the glycoprotein is released from the conjugate within 48
hours thereby yielding a biologically active glycoprotein at the
site of action in the cell. In such embodiments, the half-life of
the release is less than 48 hours, e.g., about 6, 12, 18, 24, 30,
36, 42, and 46 hours. Rapidly degradable linkers include, for
example, hydrazones and disulfides.
[0074] In other embodiments, L.sup.1 and/or L.sup.2 are/is "slowly
degradable" under the lysosomal conditions, i.e., they are more
resistant to degradation and provide for a more prolonged supply of
biologically active glycoprotein at the site of action in the cell.
The term "slowly degradable", when used in reference to a linker,
means that the linker degraded so that less than 50%, 40%, 30%,
20%, 10% or substantially none of the glycoprotein is released from
the conjugate after approximately 48 hours under the lysosomal
conditions. In such embodiments, the half-life of the release is
more than 48 hours, e.g., 50, 96, 168, 216, 240, 360, or 480
hours.
[0075] The linkers L.sup.1 and L.sup.2 are each independently
chosen preferably from alkyl (e.g., 1 to 6 carbons), carbonyl,
hydrazone, disulfide, heteroaryl, and amido, but additionally may
be chosen from alkyl, carbonyl, thiocarbonyl, ether, thioether,
ester, disulfide, amino, amido, imino, thioamido, sulfonamido,
sulfide, hydrazone, aryl, heteroaryl, cycloalkyl, and heterocyclyl.
Any of these groups can be unsubstituted or substituted with one or
more functional groups such as aldehyde, alkoxy, amido, amino,
aryl, carboxy, cyano, cycloalkyl, ester, ether, halogen,
heterocyclyl, hydroxy, ketone, nitro, sulfonate, sulfonyl, or
thiol. In some embodiments, alkyl is substituted with a carboxylic
acid or an ester thereof. In other embodiments, the ether is a
polyether such as a polyalkylene oxide, e.g., polyethylene
oxide.
[0076] In some embodiments, L.sup.1 and/or L.sup.2 comprise(s) the
hydrazone group of formula (IIa):
##STR00001##
[0077] In other embodiments, L.sup.1 and/or L.sup.2 comprise(s) the
disulfide group of formula (IIb):
##STR00002##
[0078] In some embodiments, L.sup.1 and/or L.sup.2 comprise a
hydrazone-containing group selected from formulas (III)-(VIII):
##STR00003##
wherein Ar is aryl, heteroaryl, or pyridyl such as, for
example:
##STR00004##
In some embodiments, L.sup.1 may contain 0, 1, or 2 hydrazone
groups of formula (II) and 0 or 1 disulfide groups, while in the
same conjugate L.sup.2 may contain 0 or 1 hydrazones and 0 or 1
disulfide groups. Examples of various specific embodiments are
provided in Table 3. In some embodiments, for example, L.sup.1 and
L.sup.2 each independently include 1, 2, or more hydrazone groups
and additionally a disulfide.
TABLE-US-00003 TABLE 3 Examples of The Number and Type of Labile
Groups in Linkers L.sup.1 and L.sup.2 L.sup.1 L.sup.2 Hydrazone
--S--S-- Hydrazone --S--S-- 0 0 0 0* 1 1 1 1 1 1 1 0 1 1 0 0 1 0 0
0 1 0 1 0 2 1 1 0 2 1 0 1 2 1 1 1 1 0 1 1 1 1 0 1 *In the case of
(0, 0, 0, 0), M is a masking moiety degradable under the lysosomal
conditions; in all other cases, this is optional.
[0079] For example, L.sup.1 and L.sup.2 each independently may
comprise a group selected from formulas (XIII)-(XVIII):
##STR00005##
wherein p is an integer: 2.ltoreq.p.ltoreq.12.
[0080] In some embodiments, the conjugates have a formula as shown
in (XIX)-(XXIII):
##STR00006##
[0081] In other embodiments, the conjugates have a formula as shown
in (XXIV)-(XXVIII):
##STR00007##
wherein p and q are integers; and 2.ltoreq.p.ltoreq.12 and
2.ltoreq.q.ltoreq.12 independently of each other.
Methods of Making Conjugates
[0082] Methods of making conjugates of the invention, including
those with formulas (I) and (XVII)-(XVI), comprise: (a) providing a
masking moiety comprising a first functional group and a second
functional group, (b) reacting the first functional group of the
masking moiety with the oligosaccharide side chain of a therapeutic
glycoprotein, and (b) reacting the second functional group with a
targeting moiety.
[0083] The masking moiety may contain a single type of functional
group, or it may be heterofunctional, i.e., it contains at least
two different types of functional groups. For example, the masking
moiety may be PEG that bears any one, any two, or more functional
group(s) selected from: hydrazide, hydrazine, amine, hydroxyl,
carboxylic acid, ester, thiol, maleimide, acrylate, and vinyl
sulfone.
[0084] In some embodiments, the methods of making conjugates of the
invention comprise: (a) reacting an oligosaccharide side chain of
glycoprotein G with masking moiety M to form glycoprotein-masking
moiety conjugate, and (b) reacting targeting moiety T with the
glycoprotein-masking moiety conjugate to form ternary conjugate
G(L.sup.1-M(L.sup.2-T).sub.n).sub.m. Alternatively, targeting
moiety T may be reacted first with masking moiety M to form a
"ligand-decorated" masking moiety, which is then reacted with an
oligosaccharide side chain of glycoprotein G to form ternary
conjugate G(L.sup.1-M(L.sup.2-T).sub.n).sub.m.
[0085] In some embodiments, an excess molar amount of the masking
moiety (ligand-decorated or not) is reacted with the activated
glycoprotein (e.g., more than 1, 2, 5, or 10 molar equivalents
excess).
Activation of Glycoproteins
[0086] In some embodiments, a glycoprotein is activated prior to
conjugation by introducing a reactive group at the linkage site on
the oligosaccharide side chain of the glycoprotein. For example,
the activated glycoprotein may bear an electrophilic functional
group, e.g., an aldehyde group, at the linkage site, while the
masking moiety (ligand-decorated or not) bears a nucleophilic
functional group (e.g., hydrazide) reactive to the electrophilic
group. The activated glycoprotein may further be modified to bear a
nucleophilic functional group (e.g., a thiol group) by
incorporating an adaptor molecule covalently linked to the
oligosaccharide, while the masking moiety (ligand-decorated or not)
can be made to bear an electrophilic functional group (e.g., thiol
reactive group). The thiol-reactive group can be an aryl or
heteroaryl disulfide (for example, a pyridyl disulfide). For
example, an adapter molecule, such as nipsylethylamine (NEA; see,
e.g., U.S. Pat. No. 6,749,685) or glyoxyl-nipsylethylamide (GNEA)
may be reacted with the masking moiety to form a pyridyl disulfide.
In other embodiments, the thiol reactive-group can be an aryl or
heteroaryl disulfide, vinyl sulfone, vinyl acetate, or
maleimide.
[0087] Glycoprotein activation may be accomplished either by
oxidizing sialic acid and/or other residues (e.g., using
periodate), or by first exposing galactose residues through the
removal ("trimming") of the terminal sialic acid groups (e.g.,
using an enzyme such as neuraminidase) which is then followed by
oxidation of the exposed galactose to produce a glycoprotein
functionalized with an aldehyde (e.g., using an enzyme such as
galactose oxidase (GAO)).
Incorporation of a Hydrazone Group
[0088] In some embodiments, an aldehyde is reacted with masking
moiety M (see, e.g., FIG. 2 and Example 1) or an adaptor molecule
(see, e.g., FIG. 4 and Example 7), wherein the masking moiety and
the adaptor molecule bear a reactive hydrazine group, e.g. a
hydrazide. An activated glycoprotein bearing an aldehyde group is
exchanged into a buffer with a pH of about 5.5 (e.g., 5-6) and
reacted with the hydrazide group. For example, as illustrated in
FIG. 2, hydrazide PEG (HzPEG; available commercially from, e.g.,
SunBio) is used to form a hydrazone-containing conjugate. In other
embodiments, the adapter molecule contains a thiol. For example, as
shown in FIG. 4, the adaptor molecule 3-(2-pyridyldithio)propionyl
hydrazide (PDPH) contains a protected thiol. A similar adapter
molecule bearing a hydrazide group, such as S-acetylthioacetimide
glutamic acid hydrazide (SATAGH, formed by reacting
N-succinimidyl-S-acetylthioacetate (SATA) with glutamic acid
.gamma.-hydrazide (SATA; Duncan et al., Anal. Biochem. (1983)
132:68-73) can be used. The products are then purified away from
unreacted PEG or adaptor, e.g., by anion exchange or size-exclusion
chromatography.
Incorporation of a Disulfide Group
[0089] One method of attaching a therapeutic glycoprotein and a
masking moiety (whether ligand-decorated or not) comprises: (a)
incorporating a protected thiol into an oligosaccharide side chain
of an activated glycoprotein using an adaptor molecule bearing a
protected thiol; (b) deprotecting the thiol and reacting it with a
thiol-reactive group on the masking moiety. For example, as
illustrated in FIG. 4, a glycoprotein is first reacted with an
adaptor molecule bearing a protected thiol, such as PDPH.
Alternatively, an adapter molecule bearing a protected thiol group
may be prepared by reacting SATA with glutamic acid hydrazide to
form SATAGH, which may then be reacted with a glycoprotein. The
adaptor's thiol group may then be deprotected (e.g., by reduction
of the disulfide with tris-carboxyethylphosphine (TCEP), or by
treatment of the thioacetate with hydroxylamine) to expose the
thiol, which may then be reacted with a PEG bearing thiol-reactive
groups.
[0090] The thiol reactive group on the masking moiety may be, for
example, a disulfide. In some embodiments, a disulfide may be
incorporated into PEG using an adapter molecule. For example, HzPEG
can be reacted with GNEA to form GNEA-PEG (FIG. 3). Alternatively,
a thiol-reactive PEG can be made by reacting NEA with PEG-bearing
carboxylic acid groups (FIG. 4). The resulting conjugate may be
purified (e.g., by ion-exchange chromatography) and further reacted
with a targeting moiety containing a thiol group (e.g., cysteine in
a peptide) to yield a final ternary glycoprotein/masking
moiety/targeting moiety conjugate.
Incorporation of Hydrazone and Disulfide Groups
[0091] The methods described in the previous two paragraphs can
provide linkers bearing both a hydrazone and a disulfide, for
example, by using an adapter molecule comprising both a reactive
hydrazide and a protected thiol. For example, as illustrated in
FIG. 4, a glycoprotein is reacted with the adaptor molecule PDPH,
which bears both a protected thiol group and a hydrazide group.
Alternatively, instead of PDPH, a similar adapter molecule such as
SATAGH can be used. As indicated by Duncan et al., Anal. Biochem.
(1983) 132, 68-73, the protecting acetyl group in SATA can be
released by hydroxylamine under selective conditions to expose the
thiol, which is then available to react with NEA under conditions
in which less than 20% hydrolysis of the NEA occurs from direct
hydroxylamine attack.
[0092] In other embodiments, such as those illustrated in FIG. 4,
an adaptor molecule containing a stabilized hydrazine group such
as, e.g., pyridyl hydrazide, (and optionally a thiol reactive
group) is used to conjugate the glycoprotein to the masking moiety.
Examples of such adaptor molecules include the HydraLink.TM.
reagents (SoluLink Biosciences) as described, e.g., in U.S. Pat.
Nos. 5,206,370; 5,420,285; 5,753,520; and 5,769,778 and European
Patent No. 384,769). For example, PEG-amine can be reacted with an
N-hydroxysuccinimide ester of a pyridyl hydrazine (succinimidyl
4-hydrazinonicotinate acetone hydrazone, "SANH") or terephthalic
acid hydrazide (succinimidyl 4-hydrazidoterephthalate
hydrochloride, "SHTH") to generate a PEG-pyridyl hydrazine or a
PEG-terephthalic acid hydrazide. The PEG-pyridyl hydrazine or
-terephthalic acid hydrazide can be reacted with a galactose
oxidase treated glycoprotein to yield a hydrazone. Alternatively, a
thiol reactive group may be incorporated into the stabilized
hydrazine by first reacting SANH or SHTH with NEA. The resulting
product may be reacted with a masking moiety containing a reactive
carbonyl, such as a polyanionic polysaccharide (e.g., PSA) to form
a hydrazone.
[0093] The glycoprotein/masking moiety conjugate is then further
reacted with a targeting moiety. In some embodiments, the targeting
group can be conjugated to the masking moiety via a hydrazone
linkage as illustrated in FIG. 3. Alternatively, in the case of the
targeting moiety being a peptide comprising an N-terminal serine or
threonine, the peptide may be oxidized, e.g. with sodium periodate,
to yield a glyoxyl peptide derivative. A glycoprotein/masking
moiety conjugate comprising a hydrazine may be made, for example,
by reacting PEG-amine with SANH or SHTH, followed by reaction with
a galactose oxidase treated glycoprotein. The glyoxyl peptide
derivative may then be reacted with the pyridyl hydrazine or
benzoic acid hydrazide groups on the a glycoprotein/masking moiety
conjugate to yield a ternary conjugate in which the targeting
moiety is linked via a hydrazone group. In other embodiments, a
targeting moiety that bears a thiol (e.g., cysteine in a peptide)
can be reacted with a thiol-reactive group, for example a disulfide
group in an adaptor molecule as illustrated in FIG. 4.
Conjugation with an Amino Acid Residue of a Glycoprotein
[0094] In many cases, conjugation of a masking moiety to an
oligosaccharide will produce a high degree of masking of the
oligosaccharide and inhibition of receptor binding and clearance.
However, as will be appreciated by those of ordinary skill in the
art, the distribution of glycosylation sites in the
three-dimensional structure of glycoproteins may not always provide
an optimal placement for masking critical oligosaccharide
determinants from receptor binding. For example, high mannose
oligosaccharides may be uniquely positioned and at a significant
distance from the sites of the complex oligosaccharides, which are
amenable to the conjugation chemistry described above.
[0095] Accordingly, in another embodiment, methods of making
conjugates of the invention comprise: (a) providing a masking
moiety comprising a first functional group and a second functional
group, (b) reacting the first functional group of the masking
moiety with an amino acid residue of a therapeutic glycoprotein,
and (c) reacting the second functional group with a targeting
moiety.
[0096] The methods described above for forming a conjugate of the
invention via an oligosaccharide side chain of the glycoprotein may
be also be used to form a conjugate via an amino acid residue of
the glycoprotein.
[0097] Additionally, in some embodiments, the methods of making
conjugates of the invention comprise: (a) reacting an amino acid
residue of glycoprotein G with masking moiety M to form a
glycoprotein-masking moiety conjugate, and (b) reacting targeting
moiety T with the glycoprotein-masking moiety conjugate to form
ternary conjugate G(L.sup.1-M(L.sup.2-T).sub.n).sub.m.
Alternatively, targeting moiety T may be reacted first with masking
moiety M to form a "ligand-decorated" masking moiety, which is then
reacted with an amino acid residue of glycoprotein G to form
ternary conjugate G(L.sup.1-M(L.sup.2-T).sub.n).sub.m.
[0098] In some embodiments, an amino acid residue is activated
prior to conjugation by introducing a reactive group on to the
amino acid. For example, an amino acid residue of the glycoprotein
may be activated to bear a nucleophilic functional group while the
masking moiety may bear an electrophilic functional group. In some
embodiments, the glycoprotein may be modified to bear a
nucleophilic functional group (e.g., a thiol) by incorporating an
adaptor molecule covalently linked to the amino acid residue, while
the masking moiety can be made to bear and electrophilic functional
group (e.g., a thiol-reactive group). In other embodiments, the
amino acid residue may be activated to bear an electrophilic
functional group, while the masking moiety may bear a nucleophilic
group.
[0099] In some embodiments, an excess molar amount of the masking
moiety (ligand-decorated or not) is reacted with the amino acid
residue or activated amino acid residue of a glycoprotein (e.g.,
more than 1, 2, 5, or 10 molar equivalents excess).
[0100] In one embodiment, the amino acid residue to which the
masking moiety is linked is a lysine. The lysine may be modified
with an adaptor molecule to introduce a reactive group, such as a
thiol. For example, the lysine residue may be reacted with a
thiolation reagent, such as iminothiolane (Traut's reagent), or
N-succinimidyl-S-acetylthioacetate (SATA, Duncan, R. J. S. et al.
(1983) Anal. Biochem. 132, 68-73). In one embodiment, the
thiolation reagent contains spacers, such as SATA-type reagents
containing a PEG linker such as S-acetyl-dPEG.TM..sub.4 NHS ester
(dPEG.TM..sub.4 SATA) and S-acetyl-dPEG.TM..sub.8 NHS ester
(dPEG.TM..sub.8 SATA) (Quanta Biodesign). The thiol (after
deprotection, if necessary) may be reacted with a thiol-reactive
masking moiety to form a glycoprotein-masking moiety conjugate. For
example, the thiol-modified amino acid residue may be reacted with
an NEA-PEG to form a disulfide linked glycoprotein-masking moiety
conjugate (FIG. 4B). The glycoprotein in such disulfide linked
conjugates will be susceptible to release from the masking moiety
in the strongly reducing environment of a lysosome.
[0101] In one embodiment, the thiolation reagent is SATA. In
another embodiment, the thiolation reagent is a SATA-type reagent
containing a PEG linker wherein the PEG linker is between 2 and 12
ethylene glycol units in length, or between 4 and 8 ethylene glycol
units in length, such as dPEG.TM..sub.4 SATA or dPEG.TM..sub.8
SATA, respectively.
[0102] After reaction of the thiol-modified amino acid residue with
the thiol reactive masking moiety, the resulting conjugate may be
purified, for example, by ion exchange chromatography. The
conjugate may then be reacted with a thiol-containing targeting
moiety to form the ternary conjugate. The targeting moiety may be a
peptide or protein containing a cysteine residue. Where the
targeting moiety does not contain a cysteine residue, one may be
introduced into the protein or peptide sequence or a thiol may be
introduced by chemical conjugation as described for the
glycoprotein. The ternary conjugate may be purified by
size-exclusion chromatography or by other means.
Use of a Heterobifunctional Masking Moiety
[0103] Yet another method of making ternary conjugates of the
invention involves the use of a heterobifunctional masking moiety,
for example, a masking moiety which comprises a nucleophile such
as, e.g., an aldehyde-reactive group, as a first functional group
and an electrophile such as, e.g., a thiol-reactive group, as
second functional group. Such a method comprises: (a) reacting the
heterobifunctional masking moiety with an aldehyde group on the
oxidized oligosaccharide side chain of a glycoprotein and (b)
reacting a thiol group of a targeting moiety with the
thiol-reactive on the masking moiety. (See, e.g., FIG. 3).
[0104] In some embodiments, a heterobifunctional masking moiety is
prepared from a masking moiety bearing two or more
aldehyde-reactive groups, e.g., hydrazide groups (e.g., HzPEG in
FIG. 3). As illustrated in FIG. 3, a hydrazide-functionalized PEG
is reacted with a molecule containing a hydrazide-reactive glyoxyl
aldehyde and a thiol-reactive functional group, such as GNEA, to
form a heterobifunctional PEG containing a hydrazide group and a
thiol reactive group. This heterobifunctional PEG is reacted in the
presence of galactose oxidase with a neuraminidase-treated
glycoprotein to produce a conjugate in which the PEG is coupled
through a hydrazone linkage to an exposed protein oligosaccharide.
This product is purified, and then coupled to a peptide containing
a free thiol.
Uses of Conjugates
[0105] Conjugates of invention can be used as therapeutics in
pharmaceutical compositions for treatment of mammals (e.g., human
and non-human animals). If necessary, the therapeutic effect of a
conjugate may be tested using suitable assays such as described in
the Examples and/or in vivo animal models (e.g., described in
Jeyakumar et al., Neuropath. Appl. Neurobiol. (2002) 28:343-357;
Mizukami et al., J. Clin. Invest. (2002) 109:1215-1221; Raben et
al., J. Biol. Chem. (1998) 273(30):19086-92; Marshall et al. Mol.
Ther. (2002) 6(2):179-89; Ohshima et al. Proc. Nat. Acad. Sci.
(1997) 94(6):2540-4; Horinouchi et al. Nat. Genet. (1995)
10(3):288-93; McEachern et al. J. Gene Med. (2006 Mar. 10) (Epub
ahead of print)). The data obtained from cell culture assays or
animal studies can be used in formulating dosage ranges of for use
in humans. Therapeutically effective dosages achieved in one animal
model can be converted for use in another animal, including humans,
using conversion factors (e.g., Equivalent Surface Area Dosage
factor) known in the art (see, e.g., Freireich et al. (1966) Cancer
Chemother. Reports, 50(4):219-244).
[0106] Pharmaceutical compositions will comprise a conjugate of the
invention and one or more suitable pharmaceutical excipients.
Various pharmaceutical excipient formulations are well known (see,
e.g., Physicians' Desk Reference (PDR) 2003, 57th ed., Medical
Economics Company, 2002; and Gennado et al. (eds.), Remington: The
Science and Practice of Pharmacy, 20th ed, Lippincott, Williams
& Wilkins, 2000).
[0107] The conjugates of the invention may be used to treat or
prevent various diseases and disorders including lysosomal storage
disorders listed in Table 2. One approach to treating these
diseases is enzyme replacement therapy utilizing the conjugates. In
some embodiments, the conjugates may be used to treat Fabry,
Gaucher, Pompe or Niemann-Pick B disease.
[0108] Fabry disease is a rare, inherited lysosomal storage
disorder with multisystemic effects. Patients with Fabry disease
have a defect in the gene for the lysosomal enzyme
.alpha.-galactosidase A (.alpha.-gal), also known as ceramide
trihexosidase. This defect results in an inability or diminished
ability to catabolize lipids with terminal .alpha.-galactosyl
residues. In the absence of sufficient .alpha.-gal, these lipids,
particularly globotriaosylceramide (GL-3; also known as Gb3,
ceramide trihexoside, and CTH), accumulate progressively in the
lysosomes of many cell types throughout the body. GL-3 accumulation
in renal endothelial cells may play a role in renal failure.
[0109] Gaucher disease is an inherited lysosomal storage
disorder.--In Gaucher disease, a deficiency of the enzyme acid
.beta.-glucosidase (glucocerebrosidase) leads to the accumulation
of the lipid glucocerebroside within the lysosomes of the
monocyte-macrophage system. Lipid-engorged cells with eccentric
nuclei, known as Gaucher cells, accumulate and displace healthy
normal cells in bone marrow and visceral organs, causing a host of
signs, including skeletal deterioration, anemia,
hepatosplenomegaly, and organ dysfunction. In rare cases Gaucher
cells affect the brain and nervous system.
[0110] Pompe disease is a debilitating, progressive and often fatal
lysosomal storage disorder. People born with Pompe disease have an
inherited deficiency of acid .alpha.-glucosidase. Acid
.alpha.-glucosidase assists in the breakdown of glycogen, a complex
sugar molecule stored within the lysosome. In Pompe disease, acid
.alpha.-glucosidase activity may be dramatically reduced,
dysfunctional, or non-existent, resulting in an excessive
accumulation of glycogen in the lysosome. Eventually, the lysosome
may become so clogged with glycogen that normal cellular function
is disrupted and muscle function is impaired. Although there is
glycogen storage in the cells of multiple tissues, heart and
skeletal muscles are usually the most seriously affected. Patients
typically experience progressive muscle weakness and breathing
difficulty, but the rate of disease progression can vary widely
depending on the age of onset and the extent of organ
involvement.
[0111] Niemann-Pick B disease is a lysosomal storage disorder
caused by mutations in the gene that encodes a lysosomal enzyme
called acid sphingomyelinase (ASM). Due to these mutations, the ASM
enzyme is not present in sufficient quantities to metabolize
fat-like substances. In patients with Niemann-Pick B disease,
fat-like substances, such as sphingomyelin and cholesterol,
accumulate in body tissues and organs, resulting in their
malfunction. Clinical manifestations of the disease are expressed
in tissues such as spleen, liver, and lung, and to a lesser extent
in bone marrow and lymph nodes.
[0112] Conjugates of the invention may be administered via any
route of delivery including parenteral (e.g., subcutaneous,
intravenous, intramedullary, intraarticular, intramuscular, or
intraperitoneal), transdermal, and oral (e.g., in capsules,
suspensions, or tablets). The conjugates may also be administered
by direct administration to the nervous system (e.g. direct
injection into the brain, intraventricularly, intrathecally). More
than one route can be used concurrently, if desired.
[0113] Conjugates of the present invention may be administered
alone or in conjunction with other agents, such as antihistamines
or immunosuppressants. The term "in conjunction with" indicates
that that the agent is administered at about the same time as the
conjugate. The agent can be administered contemporaneously or it
can be administered within a short time fram (e.g. within 24 hours)
of administration of the conjugate.
[0114] A therapeutically effective amount of the conjugates of the
invention may be administered at regular intervals depending on the
nature and extent of the disease's effect. A therapeutically
effective amount is a dosage amount that when administered at
regular intervals is sufficient to treat the disease such as by
ameliorating the symptoms associated with the disease, preventing
or delaying the onset of the disease and/or lessening the severity
or frequency of symptoms of the disease. Effective doses can be
extrapolated from dose response curves derived from in vitro and in
vivo data. The amount which will be therapeutically effective in
the treatment of the disease will depend on the nature and extent
of the disease effects and can also be determined by standard
clinical techniques. The appropriate therapeutically effective dose
will depend on the route of administration and the seriousness of
the disease and should be decided by a treating clinician based on
each patient's circumstances. The effective doses can be varied
(e.g. increased or decrease) over time, depending on the needs of
the individual.
[0115] Most commonly, proteinaceous compounds are administered in
an outpatient setting at regular intervals depending on the nature
and extent of disease. Administration at a "regular interval" as
used herein, indicates that the therapeutically effective dose is
administered periodocially. The interval an be determined by
standard clinical techniques. For example, the conjugate is
administered daily, weekly, biweekly, monthly, bi-monthly, or at
longer intervals. The administration for a single individual need
not be a fixed interval but can varied over time, depending on the
needs of the individual.
EXAMPLES
Example 1
Preparation of A Dihydrazide PEG Conjugate of
.alpha.-Galactosidase
[0116] One milligram of recombinant human .alpha.-galactosidase A
(.alpha.-Gal) in 50 mM sodium phosphate pH 7 was treated overnight
with 20 mU/mg Arthrobacter.TM. neuraminidase. A portion (0.5 mg) of
the product in 100 .mu.L was incubated with 100 .mu.L 10% w/v 10
kDa dihydrazide PEG (Sunbio) and 25 .mu.L 0.2 M sodium succinate pH
5.5 (final pH .about.5.8) overnight at 37.degree. C. with 9 .mu.L
of 1 mg/mL recombinant Dactylium dendroides galactose oxidase. The
product was dialyzed against 10 mM sodium phosphate pH 7 and
applied to a DEAE Sepharose.TM. column (Pharmacia) equilibrated
with the same buffer and eluted with a gradient from 0 to 0.5 M
NaCl in 10 mM phosphate pH 7. The peak fraction was concentrated
and exchanged into 0.05 M sodium phosphate pH 7 using 50 kDa MWCO
centrifugal ultrafilters (Amicon). A portion was run on a 4-12% SDS
polyacrylamide gel (NuPAGE.TM., Invitrogen) using a neutral-pH
MOPS/SDS running buffer at 200 V for 1 hour, and the gel stained
with Coomassie.TM. blue. This demonstrated approximately equal
amounts of mono- and di-PEGylated products as assessed by gel
mobility.
Example 2
pH Dependence of Hydrazide PEG Conjugate Stability
[0117] Aliquots (4 .mu.L, .about.2 .mu.g) of a DEAE Sepharose.TM.
purified dihydrazide conjugate prepared as described in Example 1
were incubated overnight in 45 .mu.L 50 mM buffer (either
phosphate, succinate, citrate, or acetate) at between pH 7.0 and
5.0 for 14 hours at 37.degree. C., and then concentrated on
Microcon.TM. 50 centrifugal ultrafilters (Amicon) for 10 minutes at
4.degree. C. The retained volumes were collected and a portion of
each run on a SDS polyacrylamide gel (NuPAGE.TM., Invitrogen) as
described in Example 1. As shown in FIG. 5, incubation at pH 7
resulted in retention of more than 80% of the PEGylated material in
PEGylated form (as compared to an unincubated control), while
reducing the pH of the solution led to a decrease in the amount of
PEGylated material. At pH 5.5, less than 10% of the initial
PEGylated material remained. There was a corresponding increase in
the free .alpha.-galactosidase.
Example 3
Effect of PEGylation on Binding of .alpha.Gal to CIMPR In Vitro
[0118] Two preparations of .alpha.-galactosidase conjugated to
either a 4-arm dendrimer ("star") hydrazide PEG (Hz4PEG) or a 8-arm
hydrazide PEG (Hz8PEG), each of 10 kDa molecular weight, in which
propionyl hydrazide groups were incorporated into the PEG main
chain at random positions (SunBio) were prepared as described in
Example 1, except that concentration of PEGs in the conjugation
step was either 0.5 or 10% w/v. The purified conjugates were
assessed for binding to purified cation-independent
mannose-6-phosphate receptor (CIMPR) by surface plasmon resonance
(Biacore). Conjugate or unmodified .alpha.-galactosidase were
diluted and pumped tangentially across a Biacore flow cell at 20
.mu.L/min. The soluble form of CIMPR (lacking the membrane anchor
sequence) was conjugated to an activated dextran-coated surface on
the optical face of the cell using NHS chemistry. Binding (assessed
by a change in refractive index) expressed in RU (resonance units),
less the RU generated by a control cell lacking receptor exposed to
the same solution after 3 minutes was plotted against the
concentration of conjugate. The data (FIG. 6) show that maximum
inhibition of binding to receptor was obtained by prior conjugation
of the enzyme with 10% w/v 4-arm (Hz4)PEG. Approximately 10-fold
higher concentration of PEG conjugate was required to produce the
same change in RU as unmodified .alpha.-galactosidase.
Example 4
In Vivo Uptake of HzPEG/.quadrature.-Galactosidase Conjugate in
Fabry Mice
[0119] A conjugate of .alpha.-galactosidase A with a 6-arm star
hydrazide PEG (20 kDa, SunBio) prepared in a similar fashion as
described in Example 1 was injected at 1 mg/kg body weight into the
tail vein of 4-month-old .alpha.-galactosidase knockout mice, and
blood samples (.about.100 .mu.L) withdrawn at various intervals.
Separate sets of mice were either injected with unmodified
.alpha.-galactosidase or enzyme co-injected with 100 mg/kg yeast
mannan (Sigma) to transiently block uptake by mannose receptor.
Serum was prepared and the amount of enzyme remaining in
circulation determined by dilution and assay using
4-methylumbelliferyl-.alpha.-D-galactoside (4MU-D-.alpha.Gal,
Sigma) as a substrate in the presence of 0.12 M
N-acetylgalactosamine to suppress .alpha.-galactosidase B activity
(Mayes et al., Clin. Chim. Acta (1981) 112:247-251) as shown in
FIG. 7. Mannan co-injection resulted in a two-fold increase in the
area under the concentration-time curve whereas PEG conjugation
resulted in a six-fold increase. The half-life of the longer-lived
PEG conjugate in circulation was approximately 4 hours.
[0120] Mice in the same experiment were sacrificed after 8 hours
and biodistribution of the conjugates was determined by enzymatic
assay on 10% w/v homogenates of the tissues prepared in 0.15%
Triton.TM. X-100, 14.5 mM citric acid, 30 mM sodium phosphate pH
4.4 using 4MU-D-.alpha.Gal as substrate. The activities in the
homogenates were normalized to protein content determined by BCA
assay (Pierce). The data shown in FIG. 8 show a significant
reduction in the uptake in liver by the PEG conjugate. Even after 8
hours, a significant amount of the recovered activity was still
present in serum.
[0121] A portion of the liver was fixed in 4% neutral-buffered
formalin overnight at 4.degree. C., embedded in paraffin, and
sectioned. Paraffin was removed from the mounted sections, which
were stained using a monoclonal antibody against the human
.alpha.-galactosidase at 2.5 .mu.g/mL, and visualized by a goat
anti-mouse horseradish peroxidase secondary antibody using
diaminobenzidine as substrate. The sections were counterstained
with Mayers Hematoxylin. Whereas the unmodified control enzyme
showed strong staining of Kupffer cells with some staining of
hepatocytes, staining of Kupffer cells was substantially reduced
with the PEGylated enzyme, while hepatocytes stained to a similar
extent.
Example 5
Preparation of an .alpha.Gal Conjugate with a Heterobifunctional
PEG
[0122] A precursor (BTNEA) was obtained by reaction of 27 mg
nipsylethylamine (NEA), 76 mg EDC, 40 mg N-hydroxysuccinimide and
37.4 mg t-BOC-threonine in 93% DMSO with 35 mM imidazole pH6
overnight at 50.degree. C. The product was purified by
reverse-phase chromatography on a 018 column (Higgins Targa),
eluting with 0.1% TFA (10 min) followed by a gradient of 0-50%
acetonitrile (1%/min) in 0.1% trifluoroacetic acid (TFA). The
product eluting at 46 minutes was collected and taken to dryness.
The product showed absorbance peaks similar to NEA (270,353 nm cf.
268,345 nm for NEA), which shifted upon reduction with TCEP
(258,308 nm cf. 256,312 nm for NEA). The product, dissolved in 100
.mu.L DMSO, was deblocked by addition of 24 .mu.L TFA, and
incubated at 50.degree. C. for 15 hours, and purified by C18
reverse phase chromatography under the same conditions (retention
time 26 min). The peak was collected and taken to dryness and then
dissolved in DMSO. The deblocked material was oxidized by reaction
with 25 mM NaIO.sub.4 in 50% DMSO-buffered with 0.05 M HEPES pH 7.4
for 15 minutes at room temperature, followed by C18 chromatography
(product GNEA eluting at 31.8 min).
[0123] An 8-arm 20 kDa MW hydrazide pendant PEG (SunBio, 1.5
.mu.mol) in which propionic acid hydrazide groups were randomly
inserted, was reacted with 1.6 .mu.mol GNEA in 50% DMSO, 0.025 M
succinate pH 5.6 (total 0.42 mL) overnight at 37.degree. C. The
reaction was diluted to 0.8 mL with cold 10 mM sodium phosphate pH
7, and dialyzed against the same buffer and then against water. The
product was recovered, lyophilized, and the NEA content determined
by reduction and absorbance at 346 nm (1.05 mol:mol PEG).
[0124] Neuraminidase-treated .alpha.Gal (0.23 mg) was reacted with
10% GNEA-PEG in 50 mM succinate pH 5.5 in the presence of 7.5 .mu.g
recombinant galactose oxidase overnight at 37.degree. C. The
product was diluted with 10 mL of 10 mM sodium phosphate pH 7 and
purified over a column of DEAE Sepharose.TM. as in Example 1.
[0125] A portion of purified GNEA PEG conjugate (25 .mu.g) was
reacted with 4.25 nmol of fluoresceinated peptides of SEQ ID NO:2
or SEQ ID NO:3 overnight at 4.degree. C. and purified away from
unreacted free peptide by elutriation on centrifugal ultrafilters
(Centricon.TM. 50, Amicon.TM. Corp). The final products contained
2.1 and 1.6 peptides per conjugate (SEQ ID NO:2 and SEQ ID NO:3,
respectively) as determined from the absorbances at 495 nm and 280
nm. A cell uptake experiment such as described in Example 8 showed
no significant increase in lysate activity after overnight
incubation with the conjugate prepared with the peptide of SEQ ID
NO:2 in the medium. In contrast, incubation with comparable amounts
of neuraminidase-treated .alpha.Gal produced over 10-fold increase
in the activity of the .alpha.Gal activity in the lysate.
Example 6
Preparation of Thiol-Reactive PEG
[0126] A 16-arm PEG in which pendant propionic acid groups are
introduced by copolymerization (SunBio, 5.25 .mu.mol) was reacted
with 126 .mu.mol nipsylethylamine (NEA), 420 .mu.mol
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDC), 168 .mu.mol
N-hydroxysuccinimide, in 1.6 mL 50% dimethylsulfoxide, 0.1 M
imidazole pH 6 overnight at 50.degree. C., yielding a two-phase
mixture. Additional 0.1 M imidazole (1.5 mL) was added and the
mixture incubated an additional 3 hours at 50.degree. C. The
product was purified by extensive dialysis against water. The NEA
content of the PEG, determined by the absorbance at 350 nm, was 9.3
NEA/PEG. A small fraction (<10%) of the PEG prepared in this
manner was bound by DEAE-Separose.TM. in 10 mM sodium phosphate pH7
buffer. This component was removed from the NEAPEG by passage over
DEAE Sepharose.TM. prior to use in conjugation reactions.
Example 7
Peptide-PEG Conjugates of .quadrature.Gal Using Hydrazide/Thiol
Chemistry
[0127] An aliquot of .alpha.-galactosidase (1.16 mg in 0.25 mL of
50 mM sodium phosphate pH 7) was treated with 20 mU/mg
Arthrobacter.TM. neuraminidase overnight at 37.degree. C. The
product was then combined with 0.125 mL 0.2 M succinate (pH 5.4),
46.5 .mu.g recombinant Dactylium galactose oxidase, and 0.05 mL 50
mM 3-(2-pyridyldithio)propionyl hydrazide (PDPH, Pierce) in a final
volume of 0.5 mL, and incubated overnight at 37.degree. C. The
product was then dialyzed overnight against cold 50 mM sodium
phosphate pH 7. The product (2.3 mg/mL) was reacted with 10 mM
tris-carboxyethylphosphine (TCEP, Pierce) to expose the thiols from
the conjugated PDPH for 10 minutes at room temperature followed by
3 rounds of desalting on 50 kDa MWCO centrifugal ultrafilters
(Oentricon.TM., Amicon.TM.) with cold degassed buffer. The product
was then reacted with 1% (w/v) of a thiol-reactive 16-arm pendant
NEA-PEG prepared as described in Example 6 in the same buffer
overnight at 4.degree. C. The reaction was dialyzed against 10 mM
sodium phosphate pH 7, loaded on an DEAE Sepharose.TM. column
equilibrated with the same buffer, and eluted with 0.25 M NaCl in
50 mM phosphate pH 7. The eluate was exchanged into 50 mM sodium
phosphate pH 7 on centrifugal ultrafilters. Aliquots (20 .mu.g
protein each) were reacted with FAM- or biotin-labeled peptides
(SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5,
AND SEQ ID NO:6) (3.75 nmol each) overnight in 50 mM sodium
phosphate pH 7 and a final volume of 50 .mu.L and purified by
desalting on 50 kDa MWCO centrifugal ultrafilters using the same
buffer. The products showed 38-56% of the specific activity of the
initial .alpha.-galactosidase. The conjugates prepared with
fluoresceinated peptides contained between 1.8 and 8.5 peptides per
protein. A diagrammatic representation of the process is shown in
FIG. 4.
Example 8
Peptide-Mediated Cell Uptake of .alpha.Gal Conjugates In Vitro
[0128] Peptide conjugates prepared in Example 7 (each 0.1 nmol/min
activity using p-nitrophenyl-.alpha.-D-galactoside as substrate)
were incubated with an immortalized wild-type murine fibroblast
cell line (TME7, Munier-Lehmann et al., J. Biol. Chem. (1996)
271:15166-15174) in 24-well plates in 0.5 mL uptake medium
(DMEM/F12 with 5% calf serum, 3% BSA and 25 mM HEPES pH 6.7) for 24
hrs in a 37.degree. C. incubator with 5% CO.sub.2. Some of the
media were supplemented with 2 mM mannose-6-phosphate (M6P) to
suppress uptake by the cation-independent M6P receptor, the major
route of uptake of the unmodified enzyme by this cell line. The
cells were washed three times with PBS pH 6.5 and lysed with
0.5.times.PBS pH 6.5, 1% Triton.TM. X-100 with protease inhibitors
(Roche), followed by brief sonication in an ice bath slurry. The
activity in the lysates were determined as described in Example 4.
Activities present in the lysates normalized to protein content as
determined by BCA assay (Pierce) are shown in FIG. 3. The
internalization of the enzyme was verified by staining cells
exposed to conjugates under similar conditions using a substrate
that produces an insoluble colored product (X-.alpha.-Gal). This
showed strong staining in the cytoplasm but not in the nucleus of
cells exposed to the R9 (SEQ ID NO:6), Tat (SEQ ID NO:2), and k9
(SEQ ID NO:5) peptide conjugates, indicating that the
cell-associated activity was internalized and not bound to the
surface of the cells.
Example 9
Use of Thioesters in the Preparation of Hydrazone-Linked Conjugates
of Lysosomal Disease Glycoproteins
[0129] One micromole of glutamic acid .gamma. hydrazide is
converted to the acetone ketal by incubation for 1 hour with 10
.mu.mol acetone in DMSO at room temperature. Then 2 .mu.mol
N-succinimidyl-S-acetylthioacetate (SATA, Pierce Chemical Co.) is
added and the incubation continued overnight at room temperature.
The product, S-acetyl thioacetamide glutamic acid hydrazide
(SATAGH), is purified by anion exchange chromatography on QAE
Sephadex.TM. in 20 mM ammonium formate pH 7, eluting with a
gradient to 0.5 M ammonium formate pH 7. The A.sub.215 peak
corresponding to the amide product is collected and lyophilized.
The cargo glycoprotein is separately desialated by overnight
digestion with 20 mU/mg Arthrobacter neuraminidase in 50 mM sodium
citrate pH 6, and then treated with 10 .mu.g/mg recombinant
galactose oxidase overnight in the same buffer. To the oxidized
glycoprotein, 5 mM SATAGH is added in 25 mM succinate pH 5.5 and
the mixture incubated at room temperature for 3 hours. The
hydrazone conjugate is purified by ultrafiltration on a
Centricon.TM. YM-30 filter or dialysis against 25 mM EDTA, 25 mM
phosphate pH 7.2. A 10-fold molar excess of a multiarm NEA-PEG is
then added along with 0.2 M hydroxylamine to deprotect the thiol,
and the mixture incubated overnight at room temperature to generate
the disulfide-linked PEG adduct.
Example 10
Use of Pyridyl Hydrazides to Generate Polysialic Acid Conjugate of
.alpha.-Galactosidase
[0130] One gram of polysialic acid PSA (colominic acid, 30 kDa avg.
MW) is dissolved at 100 mg/ml in 0.1 N NaOH and deacylated by
incubation at 37.degree. C. for 4 hours. The product is neutralized
by the addition of acetic acid to 0.1 M, and the mixture extracted
with chloroform:methanol (3:1). Sodium acetate is added to the
aqueous phase (to 0.2 M), and the PSA precipitated with 3 volumes
of ethanol followed by high speed centrifugation (10,000 g for 20
min). The pellet is washed with 85% ethanol and taken to dryness in
vacuo. The dried pellet is dissolved to 100 mg/ml with water.
Separately, a linker containing a pyridyl hydrazine coupled to
nipsylethylamine is generated by reaction of 100 .mu.mol
acetone-5-succinimidyloxycarbonyl)-pyridine-2-ylhydrazone (SANH)
(EMD Biosciences) with 150 .mu.mol nipsylethylamine overnight at
room temperature in 1 mL DMSO. To 100 mg deacylated polysialic acid
(.about.3.3 .mu.mol) is added 10 .mu.mol SANH-NEA product in 5 mL
0.1 M sodium acetate pH 5 and the mixture incubated overnight at
room temperature to form the hydrazone. The product is dialyzed
against PBS, then water, and then precipitated with ethanol as
before. The pellet is washed with 85% ethanol, taken to dryness in
vacuo, and finally re-dissolved to 100 mg/mL in water. This
material is conjugated with a reduced PDPH conjugate of .alpha.Gal
prepared as described in Example 7. The product is purified from
unconjugated PSA by diafiltration using a 50 kDa MWCO membrane, and
exchanged into 50 mM sodium phosphate pH 7.
Example 11
Synthesis of a PEG-rh.alpha.-Gal Conjugate
[0131] Fabrazyme.RTM. (recombinant human .alpha.-galactosidase) was
reacted at 5 mg/mL with a 25:1 molar excess of NHS dPEG.TM..sub.8
SATA (Quanta Biodesign) for 2 hours at 25.degree. C. in 50 mM Na
phosphate pH 7. The reaction was quenched by a 100-fold molar
excess of Tris HCl pH 7 for 30 minutes and the product purified by
dialysis. This produced 4.8 protected (S-acetyl) thiol groups per
90 kDa homodimer, as determined by reduction in free lysine content
of the enzyme by assay with trinitrobenzenesulfonic acid (TNBSA,
Pierce). The conjugate was then incubated in 50 mM hydroxylamine
hydrochloride, 2.5 mM EDTA, 50 mM Na phosphate pH 7.2 in the
presence of a 30-fold molar excess of a 6-arm (star) 20 kDa NEA-PEG
prepared as in example 6, except substituting a 6-arm star 20 kDa
carboxylic acid-terminated PEG (SunBio) as the starting material
for the pendant 16-arm PEG described in example 6. After two hours
at 25.degree. C., the reaction was buffer exchanged into 50 mM Na
phosphate pH7, 2.5 mM EDTA and incubated overnight at 25.degree. C.
The product was 100% in PEGylated form by SDS PAGE. The product was
purified by anion exchange chromatography on DEAE Sepharose,
applying the reaction product in 10 mM Na phosphate pH 7, washing
with the same buffer, and eluting with 0.25 M Na phosphate pH 7.
The product was then dialyzed into 50 mM Na phosphate pH 7.
[0132] A SATA-dPEG.sub.4-conjugate of diphtheria toxin CRM.sub.197
was separately generated by reaction of a 10-fold molar excess of
NHS SATA-dPEG.sub.4-NHS (Quanta Biodesign) with CRM197 (List
Biological Laboratories) in 10 mM Na phosphate pH 7.4 for 2 hours
at 25.degree. C., and purified by ultrafiltration against the same
buffer. A 2-fold molar excess of the SATA-dPEG.sub.4-CRM.sub.197
conjugate was then incubated with the Star-NEA-PEG-.alpha.-Gal
conjugate in 50 mM hydroxylamine hydrochloride, 2.5 mM EDTA, 50 mM
Na phosphate pH 7.2 for 2 hours at 25.degree. C. to deprotect the
linker-introduced thiols on the CRM.sub.197. The mixture was then
buffer exchanged into 2.5 mM EDTA, 50 mM Na phosphate p H7 and
incubated overnight at 25.degree. C. in the same buffer to complete
the coupling reaction. The product was purified by size-exclusion
chromatography on Superdex 200 resin in 50 mM Na phosphate pH 7.
The PEGylated product eluted as a single HMW peak which had no free
acid galactosidase or CRM.sub.197. Upon reduction, SDS PAGE
analysis showed the presence of CRM.sub.197 to acid galactosidase
subunits in approximately 1:1 ratio.
Example 12
Vero Cell Uptake of CRM PEG-.alpha.-Gal Conjugate
[0133] The CRM conjugate prepared as in example 11 or the star
PEG-.alpha.-Gal conjugate without CRM is added (5 .mu.g/mL) to
separate aliquots 0.5 mL uptake medium (Vero cell growth medium
buffered with 10 mM HEPES pH 6.7) and applied to Vero cells. To
block uptake mediated by the cation-independent mannose-6-phosphate
(M6P) receptor, 2 mM M6P is added to the medium in some wells. In
additional control wells, free CRM.sub.197 is added at a 10-fold
excess over the conjugate, and other wells receive no conjugate to
assess the endogenous level of .alpha.-galactosidase activity. The
plate is placed in an incubator overnight at 37.degree. C., 5%
CO.sub.2. The cell layers are washed 3 times with 1 mL PBS and
lysed with 1/2.times.PBS pH 6.5, 1% Triton X-100, 1.times. protease
inhibitor cocktail ("Complete", Roche). The lysates are then
assayed for acid .alpha.-galactosidase activity using
4-MU-.alpha.-galactoside substrate (Sigma) normalized to total
protein content obtained by BCA assay (Pierce). The activity in the
control wells receiving no protein (endogenous activity) is
subtracted from the activity in the wells which received protein to
determine uptake. The extent of masking is determined from the
amount of uptake which is sensitive to M6P in the medium without
and with PEGylation and/or CRM conjugation. CRM dependent uptake is
determined from the .alpha.-galactosidase uptake observed in the
wells containing the CRM conjugate less the amount of uptake
observed in wells containing excess CRM.
[0134] All publications and patents cited in this disclosure are
incorporated by reference in their entirety. To the extent the
material incorporated by reference contradicts to or is
inconsistent with this disclosure, the instant disclosure
supersedes. All examples are provided for illustration only and are
nonlimiting. Further, all numbers expressing reaction parameters
are approximate, unless expressly indicated or the context requires
otherwise.
Sequence CWU 1
1
10112PRTArtificial SequenceSynthetic Peptide 1Gly Lys Lys Lys Lys
Lys Lys Lys Lys Lys Gly Cys 1 5 10 218PRTArtificial
SequenceSynthetic Peptide 2Gly Gly Gly Tyr Gly Arg Lys Lys Gly Gly
Gln Arg Arg Arg Gly Gly 1 5 10 15 Gly Cys316PRTArtificial
SequenceSynthetic Peptide 3Gly Gly Gly Gly Gly Lys Gly Gly Gly Lys
Gly Gly Gly Gly Gly Cys 1 5 10 15 416PRTArtificial
SequenceSynthetic Peptide 4Gly Gly Gly Lys Lys Lys Lys Lys Lys Lys
Lys Lys Gly Gly Gly Cys 1 5 10 15 515PRTArtificial
SequenceSynthetic Peptide 5Gly Gly Gly Lys Lys Lys Lys Lys Lys Lys
Lys Lys Gly Gly Gly 1 5 10 15 612PRTArtificial SequenceSynthetic
Peptide 6Gly Arg Arg Arg Arg Arg Arg Arg Arg Arg Gly Cys 1 5 10
712PRTArtificial SequenceSynthetic Peptide 7Thr His Arg Pro Pro Met
Trp Ser Pro Val Trp Pro 1 5 10 87PRTArtificial SequenceSynthetic
Peptide 8Ala Ser Ser Leu Asn Ile Ala1 5 99PRTArtificial
SequenceSynthetic Peptide 9Cys Lys Gly Gly Arg Ala Lys Asp Cys1 5
107PRTArtificial SequenceSynthetic Peptide 10Gly Glu Thr Arg Ala
Pro Leu1 5
* * * * *